Omeros Corporation Submits MAA for Narsoplimab to EMA

Summary

Omeros Corporation has submitted a market authorization application (MAA) for narsoplimab to the European Medicines Agency (EMA) for the treatment of TA-TMA. The application shows a 61% response rate and improved overall survival compared to an external control group. Narsoplimab has received orphan drug designation, allowing centralized review among EU member states. The review is expected to start in mid-July, with a decision anticipated by mid-2026. This follows the US FDA’s acceptance of the resubmitted Biologics License Application, with a target action date of September 25, 2025.Reuters

Impact Analysis

First-Order Effects: The submission to the EMA is a crucial step for Omeros Corporation in expanding narsoplimab’s market reach within the EU, potentially leading to increased revenue streams from the European market if approved. The orphan drug designation provides strategic advantages, such as market exclusivity and streamlined regulatory processes. However, risks include regulatory hurdles during the review process and the time lag until mid-2026 for a potential decision.Reuters Second-Order Effects: Approval in the EU could set a precedent for other markets, influencing both regulatory perceptions and competitive dynamics within the TA-TMA treatment landscape.Reuters Investment Opportunities: Investors might consider options strategies such as call options or long positions to capitalize on potential stock price increases following positive regulatory milestones or approval decisions.Reuters